NCCN Guidelines® Insights - Myelodysplastic Syndromes, Version 3.2022
These NCCN Guidelines Insights focus on some of the updates for the 2022 version of the NCCN Guidelines, which include treatment recommendations both for lower-risk and higher-risk MDS, emerging therapies, supportive care recommendations, and genetic familial high-risk assessment for hereditary myeloid malignancy predisposition syndromes.
Category
- Myelodysplastic Syndrome
Format
- Monograph/Journal Supplement
Credits
- AAPA Category 1 CME credit
- ACPE contact hours
- AMA PRA Category 1 Credit™
- ANCC contact hours
- Participation